An adenosine analogue, IB-MECA, down-regulates estrogen receptor α and suppresses human breast cancer cell proliferation

Cancer Research

Volumn 63, Issue 19, 2003, Pages 6413-6423

  Lu, Jun ^a   Pierron, Anne ^a   Ravid, Katya ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLOROADENOSINE; ADENOSINE; ADENOSINE A3 RECEPTOR AGONIST; ADENOSINE A3 RECEPTOR ANTAGONIST; ADENOSINE DERIVATIVE; CORDYCEPIN; ESTROGEN RECEPTOR ALPHA; LIGAND; MESSENGER RNA; N6 (3 IODOBENZYL)ADENOSINE 5' N METHYLURONAMIDE; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; DNA SYNTHESIS; HELA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADENOSINE; APOPTOSIS; BREAST NEOPLASMS; CELL ADHESION; CELL DIVISION; CELL LINE, TUMOR; DOWN-REGULATION; ESTROGEN RECEPTOR ALPHA; G1 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; RECEPTOR, ADENOSINE A3; RECEPTORS, ESTROGEN; S PHASE; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 0141988684     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (79)

1. Linden, J. Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection. Annu. Rev. Pharmacol. Toxicol., 41: 775-787, 2001.
2. Gordon, J. L. Extracellular, A. T. P. effects, sources and fate. Biochem. J., 233: 309-319, 1986.
3. Ralevic, V., Milner, P., Kirkpatrick, K. A., Burnstock, G. Flow-induced release of adenosine 5′-triphosphate from endothelial cells of the rat mesenteric arterial bed. Experientia, 48: 31-34, 1992.
4. Grierson, J. P., and Meldolesi, J. Shear stress-induced [Ca2+]i transients and oscillations in mouse fibroblasts are mediated by endogenously released ATP. J. Biol. Chem., 270: 4451-4456, 1995.
5. Ferguson, D. R., Kennedy, I., and Burton, T. J. ATP is released from rabbit urinary bladder epithelial cells by hydrostatic pressure changes: a possible sensory mechanism? J. Physiol., 505 (Pt. 2): 503-511, 1997.
6. Vizi, E., Huszar, E., Csoma, Z., Boszormenyi-Nagy, G., Barat, E., Horvath, I., Herjavecz, I., and Kollai, M. Plasma adenosine concentration increases during exercise: a possible contributing factor in exercise-induced bronchoconstriction in asthma. J. Allergy Clin. Immunol., 109: 446-448, 2002.
7. Decking, U. K., Schlieper, G., Kroll, K., and Schrader, J. Hypoxia-induced inhibition of adenosine kinase potentiates cardiac adenosine release. Circ. Res., 81: 154-164, 1997.
8. Olah, M. E., and Stiles, G. L. Adenosine receptor subtypes: characterization and therapeutic regulation. Annu. Rev. Pharmacol. Toxicol., 35: 581-606, 1995.
9. Klinger, M., Freissmuth, M., and Nanoff, C. Adenosine receptors: G protein-mediated signalling and the role of accessory proteins. Cell Signalling, 14: 99-108, 2002.
10. Tey, H. B., Tan, C. H., and Khoo, H. E. Modulation of DNA synthesis via adenosine receptors in human epidermoid carcinoma (A431) cells. Biofactors, 4: 161-165, 1994.
11. Tey, H. B., Khoo, H. E., and Tan, C. H. Adenosine modulates cell growth in human epidermoid carcinoma (A431) cells. Biochem. Biophys. Res. Commun., 187: 1486-1492, 1992.
12. Colquhoun, A., and Newsholme, E. A. Inhibition of human tumour cell proliferation by analogues of adenosine. Cell Biochem. Funct., 15: 135-139, 1997.
13. Yao, Y., Sei, Y., Abbracchio, M. P., Jiang, J. L., Kim, Y. C., and Jacobson, K. A. Adenosine A3 receptor agonists protect HL-60 and U-937 cells from apoptosis induced by A3 antagonists. Biochem. Biophys. Res. Commun., 232: 317-322, 1997.
14. Kohno, Y., Sei, Y., Koshiba, M., Kim, H. O., and Jacobson, K. A. Induction of apoptosis in HL-60 human promyelocytic leukemia cells by adenosine A(3) receptor agonists. Biochem. Biophys. Res. Commun., 219: 904-910, 1996.
15. Fishman, P., Bar-Yehuda, S., and Vagman, L. Adenosine and other low molecular weight factors released by muscle cells inhibit tumor cell growth. Cancer Res., 58: 3181-3187, 1998.
16. Bast, R. E. A. Section 31. In: Cancer Medicine, Ed. 5, Vol. 5, Hamilton, Ontario, Canada: BC Decker, Inc., 2000.
17. Park, W. C., and Jordan, V. C. Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention. Trends Mol. Med., 8: 82-88, 2002.
18. Group, E. B. C. T. C. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet, 351: 1451-1467, 1998.
19. Couse, J. F., and Korach, K. S. Estrogen receptor null mice: what have we learned and where will they lead us? Endocr. Rev., 20: 358-417, 1999.
20. Hall, J. M., Couse, J. F., and Korach, K. S. The multifaceted mechanisms of estradiol and estrogen receptor signaling. J. Biol. Chem., 276: 36869-36872, 2001.
21. Foster, J. S., and Wimalasena, J. Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells. Mol. Endocrinol., 10: 488-498, 1996.
22. 1-arrested human breast cancer cells. Oncogene, 12: 2315-2324, 1996.
23. Cariou, S., Donovan, J. C., Flanagan, W. M., Milic, A., Bhattacharya, N., and Slingerland, J. M. Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. Proc. Natl. Acad. Sci. USA, 97: 9042-9046, 2000.
24. Podhajcer, O. L., Resnicoff, M., Bover, L., Medrano, E. E., Slavutsky, I., Larripa, I., and Mordoh, J. Effect of estradiol and tamoxifen on the anchorage-independent growth of the subpopulations derived from MCF-7 breast carcinoma cells: cytogenetic analysis of the stem cell subpopulation. Exp. Cell Res., 179: 58-64, 1988.
25. Horwitz, K. B., Koseki, Y., and McGuire, W. L. Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen. Endocrinology, 103: 1742-1751, 1978.
26. Manni, A., Wright, C., and Buck, H. Growth factor involvement in the multihormonal regulation of MCF-7 breast cancer cell growth in soft agar. Breast Cancer Res. Treat., 20: 43-52, 1991.
27. Neuman, E., Ladha, M. H., Lin, N., Upton, T. M., Miller, S. J., DiRenzo, J., Pestell, R. G., Hinds, P. W., Dowdy, S. F., Brown, M., and Ewen, M. E. Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4. Mol. Cell. Biol., 17: 5338-5347, 1997.
28. Cataldo, L. M., Zhang, Y., Lu, J., and Ravid, K. Rat NAP1: cDNA cloning and up-regulation by Mp1 ligand. Gene (Amst.), 226: 355-364, 1999.
29. Romieu-Mourez, R., Landesman-Bollag, E., Seldin, D. C., Traish, A. M., Mercurio, F., and Sonenshcin, G. E. Roles of IKK kinases and protein kinase CK2 in activation of nuclear factor-κB in breast cancer. Cancer Res., 61: 3810-3818, 2001.
30. Zhang, Y., Wang, Z., and Ravid, K. The cell cycle in polyploid megakaryocytes is associated with reduced activity of cyclin B1-dependent cdc2 kinase. J. Biol. Chem., 271: 4266-4272, 1996.
31. Sun, S., and Ravid, K. Role of a serine/threonine kinase, Mst1, in megakaryocyte differentiation. J. Cell Biochem., 76: 44-60, 1999.
32. Wang, Z., Zhang, Y., Lu, J., Sun, S., and Ravid, K. Mp1 ligand enhances the transcription of the cyclin D3 gene: a potential role for Sp1 transcription factor. Blood, 93: 4208-4221, 1999.
33. Pianetti, S., Guo, S., Kavanagh, K. T., and Sonenshein, G. E. Green tea polyphenol epigallocatechin-3 gallate inhibits Her-2/neu signaling, proliferation, and transformed phenotype of breast cancer cells. Cancer Res., 62: 652-655, 2002.
34. Hackett, A. J., Smith, H. S., Springer, E. L., Owens, R. B., Nelson-Rees, W. A., Riggs, J. L., and Gardner, M. B. Two syngeneic cell lines from human breast tissue: the aneuploid mammary epithelial (Hs578T) and the diploid myoepithelial (Hs578Bst) cell lines. J. Natl. Cancer Inst. (Bethesda), 58: 1795-1806, 1977.
35. DeFriend, D. J., Anderson, E., Bell, J., Wilks, D. P., West, C. M., Mansel, R. E., and Howell, A. Effects of 4-hydroxytamoxifen and a novel pure antioestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro. Br. J. Cancer, 70: 204-211, 1994.
36. Brambilla, R., Cattabeni, F., Ceruti, S., Barbieri, D., Franceschi, C., Kim, Y. C., Jacobson, K. A., Klotz, K. N., Lohse, M. J., and Abbracchio, M. P. Activation of the A3 adenosine receptor affects cell cycle progression and cell growth. Naunyn Schmiedebergs Arch. Pharmacol., 361: 225-234, 2000.
37. Kim, S. G., Ravi, G., Hoffmann, C., Jung, Y. J., Kim, M., Chen, A., and Jacobson, K. A. p53-Independent induction of Fas and apoptosis in leukemic cells by an adenosinc derivative, CI-IB-MECA. Biochem. Pharmacol., 63: 871-880, 2002.
38. Fishman, P., Bar-Yehuda, S., Madi, L., and Cohn, I. A3 adenosine receptor as a target for cancer therapy. Anticancer Drugs, 13: 437-443, 2002.
39. Hannigan, G. E., Leung-Hagesteijn, C., Fitz-Gibbon, L., Coppolino, M. G., Radeva. G., Filmus, J., Bell, J. C., and Dedhar, S. Regulation of cell adhesion and anchorage-dependent growth by a new β1-integrin-linked protein kinase. Nature (Lond.), 379: 91-96, 1996.
40. Fishman, P., Bar-Yehuda, S., Ohana, G., Pathak, S., Wasserman, L., Barer, F., and Multani, A. S. Adenosine acts as an inhibitor of lymphoma cell growth: a major role for the A3 adenosine receptor. Eur. J. Cancer, 36: 1452-1458, 2000.
41. Fredholm, B. B., Ijzerman, A. P., Jacobson, K. A., Klotz, K. N., and Linden, J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev., 53: 527-552, 2001.
42. von Lubitz, D. K. Adenosine A3 receptor and brain. A culprit, a hero, or merely yet another receptor? Ann. N. Y. Acad. Sci., 825: 49-67, 1997.
43. Aitken, S. C., and Lippman, M. E. Hormonal regulation of net DNA synthesis in MCF-7 human breast cancer cells in tissue culture. Cancer Res., 42: 1727-1735, 1982.
44. 1 phase of the cell cycle. Eur. J. Cancer Clin. Oncol., 19: 615-621, 1983.
45. Lippman, M., Bolan, G., and Huff, K. The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res., 36: 4595-4601, 1976.
46. 1 phase. Cancer Res., 43: 3583-3585, 1983.
47. Kodama, F., Greene, G. L., and Salmon, S. E. Relation of estrogen receptor expression to clonal growth and antiestrogen effects on human breast cancer cells. Cancer Res., 45: 2720-2724, 1985.
48. Goldenberg, G. J., and Froese, E. K. Drug and hormone sensitivity of estrogen receptor-positive and -negative human breast cancer cells in vitro. Cancer Res., 42: 5147-5151, 1982.
49. Wijayaratne, A. L., and McDonnell, D. P. The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators. J. Biol. Chem., 276: 35684-35692, 2001.
50. Borras, M., Laios, I., el Khissiin, A., Seo, H. S., Lempereur, F., Legros, N., and Leclercq, G. Estrogenic and antiestrogenic regulation of the half-life of covalently labeled estrogen receptor in MCF-7 breast cancer cells. J. Steroid Biochem. Mol. Biol., 57: 203-213, 1996.
51. McPherson, L. A., Baichwal, V. R., and Weigel, R. J. Identification of ERF-1 as a member of the AP2 transcription factor family. Proc. Natl. Acad. Sci. USA, 94: 4342-4347, 1997.
52. Saceda, M., Lindsey, R. K., Solomon, H., Angeloni, S. V., and Martin, M. B. Estradiol regulates estrogen receptor mRNA stability. J. Steroid Biochem. Mol. Biol., 66: 113-120, 1998.
53. Ing, N. H., and Ott, T. L. Estradiol up-regulates estrogen receptor a messenger ribonucleic acid in sheep endometrium by increasing its stability. Biol. Reprod., 60: 134-139, 1999.
54. Kenealy, M. R., Flouriot, G., Sonntag-Buck, V., Dandekar, T., Brand, H., and Gannon, F. The 3′-untranslated region of the human estrogen receptor α gene mediates rapid messenger ribonucleic acid turnover. Endocrinology, 141: 2805-2813, 2000.
55. Brown, A. M., Jeltseh, J. M., Roberts, M., and Chambon, P. Activation of pS2 gene transcription is a primary response to estrogen in the human breast cancer cell line MCF-7. Proc. Natl. Acad. Sci. USA, 81: 6344-6348, 1984.
56. Mosselman, S., Polman, J., and Dijkema, R. ER β: identification and characterization of a novel human estrogen receptor. FEBS Lett., 392: 49-53, 1996.
57. Robak, T. The role of nucleoside analogues in the treatment of chronic lymphocytic leukemia-lessons learned from prospective randomized trials. Leuk. Lymphoma, 43: 537-548, 2002.
58. Williams, W., Craver, R. D., Correa, H., Velez, M., and Gardner, R. V. Use of 2-chlorodeoxyadenosine to treat infantile myofibromatosis. J. Pediatr. Hematol. Oncol., 24: 59-63, 2002.
59. Koc, Y., Urbano, A. G., Sweeney, E. B., and McCaffrey, R. Induction of apoptosis by cordycepin in ADA-inhibited TdT-positive leukemia cells. Leukemia (Baltimore), 10: 1019-1024, 1996.
60. Schrier, S. M., van Tilburg, E. W., van der Meulen, H., Ijzerman, A. P., Mulder, G. J., and Nagelkerke, J. F. Extracellular adenosine-induced apoptosis in mouse neuroblastoma cells: studies on involvement of adenosine receptors and adenosine uptake. Biochem. Pharmacol., 61: 417-425, 2001.
61. Barbieri, D., Abbracchio, M. P., Salvioli, S., Monti, D., Cossarizza, A., Ceruti, S., Brambilla, R., Cattabeni, F., Jacobson, K. A., and Franceschi, C. Apoptosis by 2-chloro-2′-deoxy-adenosine and 2-chloro-adenosine in human peripheral blood mononuclear cells. Neurochem. Int., 32: 493-504, 1998.
62. Kos, M., Reid, G., Denger, S., and Gannon, F. Minireview: genomic organization of the human ERα gene promoter region. Mol. Endocrinol., 15: 2057-2063, 2001.
63. Reid, G., Denger, S., Kos, M., and Gannon, F. Human estrogen receptor-alpha: regulation by synthesis, modification and degradation. Cell Mol. Life Sci., 59: 821-831, 2002.
64. Cohn, C. S., Sullivan, J. A., Kiefer, T., and Hill, S. M. Identification of an enhancer element in the estrogen receptor upstream region: implications for regulation of ER transcription in breast cancer. Mol. Cell Endocrinol., 158: 25-36, 1999.
65. Wakeling, A. E., Dukes, M., and Bowler, J. A potent specific pure antiestrogen with clinical potential. Cancer Res., 51: 3867-3873, 1991.
66. Pink, J. J., and Jordan, V. C. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. Cancer Res., 56: 2321-2330, 1996.
67. Fan, M., Bigsby, R. M., and Nephew, K. P. The NEDD8 pathway is required for proteasome-mediated degradation of human estrogen receptor (ER)-α and essential for the antiproliferative activity of ICI 182,780 in ERα-positive breast cancer cells. Mol. Endocrinol., 17: 356-365, 2003.
68. Lykkesfeldt, A. E., Larsen, S. S., and Briand, P. Human breast cancer cell lines resistant to pure anti-estrogens are sensitive to tamoxifen treatment. Int. J. Cancer, 61: 529-534, 1995.
69. Jones, J. L., Daley, B. J., Enderson, B. L., Zhou, J. R., and Karlstad, M. D. Genistein inhibits tamoxifen effects on cell proliferation and cell cycle arrest in T47D breast cancer cells. Am. Surg., 68: 575-577; discussion 577-578, 2002.
70. Fontana, J. A. Interaction of retinoids and tamoxifen on the inhibition of human mammary carcinoma cell proliferation. Exp. Cell Biol., 55: 136-144, 1987.
71. Dardes, R. C., O'Regan, R. M., Gajdos, C., Robinson, S. P., Bentrem, D., De Los Reyes, A., and Jordan, V. C. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo. Clin. Cancer Res., 8: 1995-2001, 2002.
72. Cavailles, V., Gompel, A., Portois, M. C., Thenol, S., Mabon, N., and Vignon, F. Comparative activity of pulsed or continuous estradiol exposure on gene expression and proliferation of normal and tumoral human breast cells. J. Mol. Endocrinol., 28: 165-175, 2002.
73. Green, D. R., and Reed, J. C. Mitochondria and apoptosis. Science (Wash. DC), 281: 1309-1312, 1998.
74. Wajant, H. The Fas signaling pathway: more than a paradigm. Science (Wash. DC), 296: 1635-1636, 2002.
75. Vousden, K. H. p53: death star. Cell, 103: 691-694, 2000.
76. Franke, T. F., Kaplan, D. R., and Cantley, L. C. PI3K: downstream AKTion blocks apoptosis. Cell, 88: 435-437, 1997.
77. Datta, S. R., Brunet, A., and Greenberg, M. E. Cellular survival: a play in three Akts. Genes Dev., 13: 2905-2927, 1999.
78. Gao, Z., Li, B. S., Day, Y. J., and Linden, J. A3 adenosine receptor activation triggers phosphorylation of protein kinase B and protects rat basophilic leukemia 2H3 mast cells from apoptosis. Mol. Pharmacol., 59: 76-82, 2001.
79. Bezwoda, W. R., and Meyer, K. Effect of α-interferon, 17β-estradiol, and tamoxifen on estrogen receptor concentration and cell cycle kinetics of MCF 7 cells. Cancer Res., 50: 5387-5391, 1990.